Table 5.
Morning peak expiratory flow (mPEF), area under the curve (AUC) change from baseline in subgroups defined by four different biomarkers: serum IL‐18 fold change, serum TRAIL fold change, eosinophils (109/L) at baseline and neutrophils (109/L) at baseline
| Biomarker (Q1,Q3) | Treatment period | mPEF difference AZD9412 – Placebo, (p‐value) | ||
|---|---|---|---|---|
|
Low group marker < Q1 |
Mid group Q1 ≤ marker ≤Q3 |
High group marker > Q3 |
||
| IL18 FCH (0.88,1.25) | Days 1 to 7 | 49.5 (0.0007) | 32.8 (0.008) | −4.9 (0.76) |
| Days 1 to 14 | 38.9 (0.02) | 28.0 (0.054) | −7.22 (0.73) | |
| EOSINOPHILS (0.15, 0.33) | Days 1 to 7 | −0.06 (0.99) | 21.1 (0.04) | 56.1 (0.005) |
| Days 1 to 14 | −2.1 (0.94) | 27.7 (0.014) | 53.2 (0.021) | |
| NEUTROPHILS (3.4,5.84) | Days 1 to 7 | 38.5 (0.15) | 18.6 (0.09) | 5.1 (0.71) |
| Days 1 to 14 | 13.8 (0.62) | 14.3 (0.23) | 14.5 (0.41) | |
| TRAIL FCH (0.81, 1.36) | Days 1 to 7 | −19.5(0.21) | 30.9 (0.009) | 9.3 (0.58) |
| Days 1 to 14 | −26.3 (0.14) | 25.4 (0.073) | 20.0 (0.35) | |
These biomarkers were selected from a total of 19 biomarkers, as those which showed an indication of being predictive of morning PEF, AUC change from baseline in a multiple regression model.
Abbreviations: FCH, fold change; IL‐, interleukin; L, litre; Q, quartile; TRAIL, TNF‐related apoptosis inducing ligand.